Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
$80.76
$0.08(0.16%)
At close: 4:00 PM EST
$80.76
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$49.00 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)633.92K
Market Cap
$8.39B
Enterprise Value$9.51B
Total Cash (Recent Filing)$421.68M
Total Debt (Recent Filing)$6.36M
Price to Earnings (P/E)91.2
Beta0.50
Next Earnings
Feb 18, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding105,188,220
10 Day Avg. Volume475,451
30 Day Avg. Volume633,925
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)7.65
Price to Sales (P/S)7.71
P/FCF Ratio26.55
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue12.83
Enterprise Value/Gross Profit13.07
Enterprise Value/Ebitda131.25
Forecast
1Y Price Target
$135.33Price Target Upside67.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1
Revenue Forecast (FY)$819.25M
Bulls Say, Bears Say
Bulls Say
Financial PositionCorcept reported cash and cash equivalents of $421.0M, which is believed to be sufficient to fund operations for the foreseeable future.
Market ExclusivityRelacorilant benefits from multiple patents and orphan drug designation, offering market exclusivity in the US and EU, which could protect against generic threats.
Regulatory ApprovalsRelacorilant has a 90% probability of FDA approval for Cushing’s syndrome due to successful Phase 3 studies showing superior efficacy and safety.
Bears Say
Distribution ChallengesThe departure of Optime Care, the exclusive distributor for Korlym, has delayed Corcept's strategy to have at least two pharmacies operational, affecting near-term sales projections.
Revenue GuidanceManagement has once again lowered their revenue guidance, currently revising it to a $50M decline.
Supply Chain IssuesCorcept continued to experience persistent headwinds related to a higher mix of authorized generic (AG) of Korlym as well as supply chain issues with their specialty pharmacy distribution.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $49.00 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $8.39B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Feb 18, 2026 which is in 77 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Nov 04, 2025. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.164 by -$0.004.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.38.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,188,220 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.16 in its last earnings report, missing expectations of $0.164. Following the earnings report the stock price went up 7.806%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.33 (67.57% Upside)
$135.33 (67.57% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 343.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $364.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.31%
12-Months-Change
Fundamentals
Return on Equity
16.47%
Trailing 12-Months
Asset Growth
5.02%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and a robust pipeline, particularly in hypercortisolism and oncology. However, challenges such as a significant decline in net income and unresolved patent litigation present concerns.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$135.33
▲(67.57% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.43% Insiders
16.68% Mutual Funds
12.29% Other Institutional Investors
38.88% Public Companies and Individual Investors